Women's Input on Sexual Health

NCT ID: NCT02057419

Last Updated: 2025-10-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-14

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to answer the following question: How do user sensory perceptions and experiences (USPEs) for IVRS differ between initial and continued use and how can this knowledge help product developers better understand how to design new IVR products and develop behavioral (or point-of-care) interventions to optimize use?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Sexual and reproductive health (SRH) is a global public health priority. Providing efficacious SRH technologies that have the greatest likelihood of use will have the greatest impact on women's health. Critical to use is "acceptability." However, current conceptualizations of adherence and acceptability fail to fully articulate and account for the user experience. Given the recent development of various IVR technologies and the potential for multipurpose technologies, the impact on global public health would be far-reaching, affecting reproductive health in women and men: decreasing STI incidence, minimizing unplanned pregnancies, and decreasing morbidity and mortality due to a range of other reproductive health conditions.

Condition: Participants will use an IVR for a period of three months and report sensory perceptions and use experiences.

Methodology and Data Collection: Volunteers (N\~6-10) will first be screened for the study using a brief questionnaire. Those who are interested in contraception and are eligible based on their responses to the prescreen will then complete a clinical screening visit and pregnancy test. Once enrolled participants will complete a survey that asks questions about demographics and sexual and reproductive history.

During the course of the study, participants will evaluate their use of an IVR. IVRs will be used for three consecutive months. They will be given a three-month supply of the product at the beginning of the use period. About once a month, each participant will be required to complete a web survey about their experience with the study product.

All participants complete a final survey that will ask about their experiences with the study product.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intravaginal Ring Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravaginal Ring Users

Use IVR for 3-month period and report user sensory perceptions and experiences.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* are between the ages of 18 and 45 at prescreening,
* report vaginal sex with a man in the past month at prescreening,
* are not pregnant (self-report, confirmed at V1, V2, and V3 by urine HcG test) and report no intention to become pregnant during the course of the study,
* report negative or unknown HIV status,
* report a need for contraceptive products and
* are willing and able to provide informed consent.

Exclusion Criteria

* self-report pregnancy, have a positive urine pregnancy test at Visits 1, 2, or 3, or intend to become pregnant during the course of the study,
* self-report breast feeding,
* self-report a vaginal delivery or other reproductive surgical procedure in the past 30 days,
* self-report being HIV-positive,
* self-report being diagnosed with or having an active sexually transmitted infection (STI) in the past 12 months,
* self-report an allergy or sensitivity to any of the study products,
* do not have a cell phone or internet access,
* are unable or unwilling to give informed consent, or
* have any condition that, in the opinion of the study clinician(s) or principle investigator, would compromise the participant's ability to participate in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role collaborator

The Miriam Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kate Guthrie, PhD

Role: PRINCIPAL_INVESTIGATOR

The Miriam Hospital: Centers for Behavioral & Preventive Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Miriam Hospital: Centers for Behavioral & Preventive Medicine

Providence, Rhode Island, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K24HD062645

Identifier Type: NIH

Identifier Source: secondary_id

View Link

TMH-506070

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.